Drug recall · April 25, 2018
Lupin Cefdinir powder for Oral Suspension USP recall
Why: Superpotent Drug
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Lupin Cefdinir powder for Oral Suspension USP, 250 mg/5 mL in (a) 60 mL packs ( NDC 68180-723-20) and (b) 100 mL packs ( 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202
- Lots / codes
Lot # F602241; Exp. 10/18 Lot # F602577; Exp. 11/18 Lot # F700036; Exp. 12/18
- Quantity
- 40,824 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Nationwide
- Initiated
- March 27, 2018 · Voluntary: Firm initiated
- Classified
- April 17, 2018
- Reported
- April 25, 2018
- Ended
- April 15, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefdinir
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.